Roche suffered even as Franc sales continue to get easier to print into dollars getting it $12 billion in sales while price cuts by DM governments, currency appreciation and losing franchises ( down 50% in Tamiflu and even for cancer drug Avastin) got a disappointing picture emerging. The company is expecting to end 2011 with a near double digit EPS performance and going by big pharma restructuring would be comparable to Pfizer in sales after it drawsdown on its restructuring plan and manages to lose the much talked $12 billion Lipitor to Generics
No comments:
Post a Comment